LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Home・Aandelen Lijst・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Gesloten

SectorGezondheidszorg

70.86 6.81

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

66.39

Max

73.84

Belangrijke statistieken
By Trading Economics
Inkomsten	292M 150M
Verkoop	-75M 377M
K/W Sectorgemiddelde	25.941 51.415
Winstmarge	39.832
Werknemers	423
EBITDA	-97M 185M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+27.21% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	218M 7.9B
Vorige openingsprijs	64.05
Vorige sluitingsprijs	70.86

Nieuwssentiment

By Acuity

27%

73%

70 / 346 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

60.49 / 70.14 Steun & Weerstand

Halozyme Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 mei 2026, 22:50 UTC

Winsten

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 mei 2026, 22:49 UTC

Winsten

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 mei 2026, 22:32 UTC

Winsten

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 mei 2026, 23:48 UTC

Marktinformatie

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 mei 2026, 22:57 UTC

Marktinformatie

Winsten

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 mei 2026, 22:26 UTC

Winsten

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 mei 2026, 22:25 UTC

Winsten

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 mei 2026, 22:25 UTC

Winsten

Aristocrat Leisure Interim Dividend A$0.50/Security

12 mei 2026, 22:24 UTC

Winsten

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 mei 2026, 22:23 UTC

Winsten

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 mei 2026, 22:23 UTC

Winsten

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 mei 2026, 22:19 UTC

Winsten

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 mei 2026, 22:14 UTC

Winsten

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 mei 2026, 22:14 UTC

Winsten

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 mei 2026, 22:13 UTC

Winsten

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 mei 2026, 22:12 UTC

Winsten

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 mei 2026, 22:12 UTC

Winsten

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 mei 2026, 22:11 UTC

Winsten

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 mei 2026, 22:11 UTC

Winsten

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 mei 2026, 22:10 UTC

Winsten

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 mei 2026, 22:09 UTC

Winsten

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 mei 2026, 22:09 UTC

Winsten

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 mei 2026, 22:08 UTC

Winsten

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 mei 2026, 22:07 UTC

Winsten

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 mei 2026, 22:06 UTC

Winsten

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 mei 2026, 22:06 UTC

Winsten

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 mei 2026, 22:05 UTC

Winsten

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 mei 2026, 22:04 UTC

Winsten

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Peer Vergelijking

Prijswijziging

Halozyme Therapeutics Inc Prognose

Koersdoel

By TipRanks

27.21% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 84.48 USD 27.21%

Hoogste 96 USD

Laagste 66.41 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Halozyme Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Halozyme Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

60.49 / 70.14Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

70 / 346 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.